ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
港股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
長春高新技術產業(集團)股份有限公司(臨時代碼)
成交量:
- -
成交額:
- -
市值:
- -
市盈率:
- -
高:
- -
開:
- -
低:
- -
收:
- -
52周最高:
- -
52周最低:
- -
股本:
- -
香港流通股本:
- -
量比:
- -
換手率:
- -
股息:
- -
股息率:
- -
淨資產收益率:
--
總資產收益率:
--
市淨率:
--
市盈率(LYR):
- -
市銷率:
- -
資料載入中...
總覽
公司
新聞資訊
公告
長春高新(000661.SZ):GenSci142膠囊境內生產藥品註冊臨牀試驗申請獲批准
智通财经
·
11/27
「東北藥茅」長春高新擬赴港上市 證監會就募資用途等問題要求補充説明
红星资本局
·
11/17
新股消息 | 長春高新(000661.SZ)擬港股上市 中國證監會要求補充説明募集資金用途等
智通财经
·
11/14
長春高新:港交所審批後續需獲證監會備案並通過聯交所聆訊
新浪财经
·
11/06
長春高新(000661.SZ):GenSci134注射液境內生產藥品註冊臨牀試驗申請獲批准
智通财经
·
11/03
葵花葯業收警示函,達嘉維康副總經理辭職,長春高新1類新藥獲批臨牀,貝達藥業與晟斯生物達成戰略合作
谈医说药
·
11/02
長春高新:金蓓欣2025年6月底獲批後,7月中旬開始上市銷售,目前銷售情況良好
证券日报
·
10/31
長春高新(000661.SZ)發佈前三季度業績,歸母淨利潤11.65億元,同比下降58.23%
智通财经
·
10/30
長春高新大變局,誰「擠壓」了利潤?
蓝鲸财经
·
10/23
長春高新(000661.SZ):注射用GenSci139境內生產藥品臨牀試驗獲批
智通财经
·
10/20
淨利潤暴跌42%、三費高企46%!長春高新赴港上市難掩「內憂外患」
市场资讯
·
10/20
長春高新(000661.SZ):注射用GenSci143臨牀試驗申請獲受理
智通财经
·
10/17
昔日超級大牛股長春高新,擬赴港上市!
市场资讯
·
10/15
九成收入依賴六款產品,集採後業績暴跌,「東北藥茅」長春高新啓動「A+H」計劃
蓝鲸财经
·
10/14
長春高新(000661.SZ)子公司三價流感病毒裂解疫苗(BK-01佐劑)臨牀試驗申請獲批准
智通财经
·
10/13
「東北藥茅」長春高新申請赴港上市,業績滑坡、市值縮水超1600億元
《理财周刊》
·
10/11
長春高新押注脱敏市場求解背後:集採壓價與競爭加劇成掣肘
市场资讯
·
10/08
天壇生物高管辭職,長春高新擬赴港上市,恆瑞醫藥1類新藥獲批臨牀,羅欣藥業擬定增募資8.42億元
谈医说药
·
09/29
長春高新(000661.SZ)子公司替勃龍片在境內獲批上市
智通财经
·
09/29
新股消息 | 長春高新衝刺港交所,連續8年躋身「中國醫藥工業百強企業排行榜」
智通财经
·
09/29
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/91272/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"91272","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91272\",,,,,undefined,":{"symbol":"91272","market":"HK","secType":"STK","nameCN":"長春高新技術產業(集團)股份有限公司(臨時代碼)","latestPrice":0,"timestamp":1764921600000,"preClose":0,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":0,"latestTime":"12-05 16:00:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":0,"adr":0,"exchange":"SEHK","adjPreClose":0,"openAndCloseTimeList":[[1764898200000,1764907200000],[1764910800000,1764921600000]],"volumeRatio":0,"lotSize":0,"spreadScale":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"91272\",,,,,undefined,":{"symbol":"91272","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/91272\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"91272\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"91272\",market:\"HK\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"91272\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2586546243","title":"長春高新(000661.SZ):GenSci142膠囊境內生產藥品註冊臨牀試驗申請獲批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2586546243","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586546243?lang=zh_tw&edition=fundamental","pubTime":"2025-11-27 16:55","pubTimestamp":1764233713,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新(000661.SZ)公告,公司子公司长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,金赛药业GenSci142胶囊注册临床试验申请获得批准。据悉,GenSci142胶囊是金赛药业开发的一款1类创新生物制品,拟用于细菌性阴道病的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0075","BK0046","91272","BK0188","BK0239","BK0028","000661","BK0057"],"gpt_icon":0},{"id":"2584606794","title":"「東北藥茅」長春高新擬赴港上市 證監會就募資用途等問題要求補充説明","url":"https://stock-news.laohu8.com/highlight/detail?id=2584606794","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584606794?lang=zh_tw&edition=fundamental","pubTime":"2025-11-17 22:35","pubTimestamp":1763390100,"startTime":"0","endTime":"0","summary":" 11月17日消息,在9月底递表港交所后,“生长激素一哥”长春高新 近日收到证监会境外发行上市备案补充材料要求。 11月14日,证监会共对10家拟港股上市企业出具补充材料要求。其中,证监会就长春高新募集资金用途、下属子公司开展相关业务及具体运营情况等问题要求长春高新进行补充说明。然而,也因为过度依赖生长激素业务,且公司带状疱疹疫苗遭遇挫折,2024年及2025年上半年,长春高新营收、净利润双双出现下滑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-17/doc-infxtqvw4711065.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0188","91272","BK0046","000661","BK0057","BK0028","BK0075"],"gpt_icon":0},{"id":"2583508022","title":"新股消息 | 長春高新(000661.SZ)擬港股上市 中國證監會要求補充説明募集資金用途等","url":"https://stock-news.laohu8.com/highlight/detail?id=2583508022","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583508022?lang=zh_tw&edition=fundamental","pubTime":"2025-11-14 19:48","pubTimestamp":1763120916,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,11月14日,中国证监会公布《境外发行上市备案补充材料要求》。中国证监会国际司公示10家企业补充材料要求,其中,公示提到要求长春高新补充说明公司募集资金用途、以及业务涉及AI大模型的具体情况等。据港交所9月29日披露,长春高新技术产业(集团)股份有限公司向港交所主板提交上市申请书,中信建投国际为其独家保荐人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0075","91272","BK0188","BK0057","BK0046","000661","BK0239"],"gpt_icon":0},{"id":"2581662068","title":"長春高新:港交所審批後續需獲證監會備案並通過聯交所聆訊","url":"https://stock-news.laohu8.com/highlight/detail?id=2581662068","media":"新浪财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581662068?lang=zh_tw&edition=fundamental","pubTime":"2025-11-06 17:00","pubTimestamp":1762419600,"startTime":"0","endTime":"0","summary":"投资者提问:谢谢回复!请问港交所的审批流程是怎样的?能具体介绍一下吗?谢谢!董秘回答(长春高新SZ000661):您好,对于公司来说,后续需要取得中国证监会的备案并需通过联交所聆讯,谢谢!查看更多董秘问答>>免责声明:本信息由新浪财经从公开信息中摘录,不构成任何投资建议;新浪财经不保证数据的准确性,内容仅供参考。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106172631a6e58e29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251106172631a6e58e29&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HKXCY","LU0197773673.USD","LU0516422440.USD","LU0594300419.USD","LU1242518857.USD","LU0821914370.USD","LU1051768304.USD","LU0651947912.USD","LU0197773160.USD","LU0348825331.USD","LU1282649141.HKD","LU1051769294.HKD","LU1048596156.SGD","LU0084288322.USD","LU1226287529.USD","LU1282648689.USD","LU1981816686.USD","LU1515016050.SGD","80388","LU0320764599.SGD","LU0456846285.SGD","LU1211504680.USD","LU1734074674.USD","HEXmain","SG9999001051.SGD","LU0651946864.USD","LU1993786604.SGD","LU0797268264.HKD","LU1807302812.USD","LU0417516902.SGD","IE00B3T34201.USD","LU1023057109.AUD","LU0359202008.SGD","LU1481107354.HKD","LU1366334651.USD","LU0918141705.HKD","LU0417516738.SGD","LU0819123356.HKD","LU1642822792.SGD","LU0370786039.SGD","LU0918141887.USD","LU0708995583.HKD","91272","LU0819121731.USD","LU0516423091.SGD","LU0261947096.USD","BK1610","00388","LU0048597586.USD","LU0106959298.USD"],"gpt_icon":0},{"id":"2580291336","title":"長春高新(000661.SZ):GenSci134注射液境內生產藥品註冊臨牀試驗申請獲批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2580291336","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580291336?lang=zh_tw&edition=fundamental","pubTime":"2025-11-03 19:00","pubTimestamp":1762167629,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新(000661.SZ)公告,公司子公司长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,金赛药业GenSci134注射液的境内生产药品注册临床试验申请获得批准。公告显示,GenSci134注射液是金赛药业自主研发的一款治疗用生物制品1类药物,拟用于生长激素缺乏症(GHD)包括成人生长激素缺乏症(AGHD)、儿童生长激素缺乏症(PGHD)和非GHD(包括ISS等)患者的治疗。本次申请针对的是特发性身材矮小(ISS)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","91272","BK0028","BK0057","BK0046","BK0239","000661","BK0075"],"gpt_icon":0},{"id":"2580237622","title":"葵花葯業收警示函,達嘉維康副總經理辭職,長春高新1類新藥獲批臨牀,貝達藥業與晟斯生物達成戰略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2580237622","media":"谈医说药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580237622?lang=zh_tw&edition=fundamental","pubTime":"2025-11-02 22:49","pubTimestamp":1762094989,"startTime":"0","endTime":"0","summary":"长春高新:公司子公司长春金赛药业有限责任公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,金赛药业GenSci134注射液的境内生产药品注册临床试验申请获得批准。相关数据显示,左卡尼汀注射液2024年度中国院内市场规模为1.03亿支,销售金额为9.65亿元。截至公告披露日,左卡尼汀注射液累计投入的研发费用为376万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251102225411a483022f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251102225411a483022f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["91272","BK1161","91287","06628"],"gpt_icon":0},{"id":"2579245942","title":"長春高新:金蓓欣2025年6月底獲批後,7月中旬開始上市銷售,目前銷售情況良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2579245942","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579245942?lang=zh_tw&edition=fundamental","pubTime":"2025-10-31 16:37","pubTimestamp":1761899820,"startTime":"0","endTime":"0","summary":"证券日报网讯长春高新10月31日发布公告,在公司回答调研者提问时表示,金蓓欣2025年6月底获批后,7月中旬开始上市销售,目前销售情况良好,2025年第三季度已经实现销售收入超过5500万元。公司目前已搭建两百余人的销售团队,也在迅速提升医院、渠道等覆盖率。后续,公司将进一步集中资源,重点推进相关具备较高市场潜力的重点新产品,努力推动相关新业务成为公司新的业绩增长点,进一步推进公司多元化转型升级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-31/doc-infvupap8703462.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-31/doc-infvupap8703462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["91272","BK0057","BK0075","BK0188","BK0239","BK0046","BK0028","000661"],"gpt_icon":0},{"id":"2579121279","title":"長春高新(000661.SZ)發佈前三季度業績,歸母淨利潤11.65億元,同比下降58.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579121279","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579121279?lang=zh_tw&edition=fundamental","pubTime":"2025-10-30 23:40","pubTimestamp":1761838825,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新(000661.SZ)发布2025年三季度报告,前三季度,公司实现营业收入98.07亿元,同比下降5.60%。归属于上市公司股东的净利润11.65亿元,同比下降58.23%。归属于上市公司股东的扣除非经常性损益的净利润12.69亿元,同比下降55.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363251.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["91272","000661"],"gpt_icon":0},{"id":"2577328271","title":"長春高新大變局,誰「擠壓」了利潤?","url":"https://stock-news.laohu8.com/highlight/detail?id=2577328271","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577328271?lang=zh_tw&edition=fundamental","pubTime":"2025-10-23 11:37","pubTimestamp":1761190620,"startTime":"0","endTime":"0","summary":"文|《投资者网》蔡俊近期,长春高新正式向港交所递交主板上市申请。截至目前,公司市值约500亿元左右。早前,公司的首次尝试未能收效,其化整为零的路径造成净利率明显下滑。随后,公司表示经营情况一切正常。公司在相关财报中,也把净利润的降速归于组织架构重设引发的费用调整、增长。公司表示,内部重构期间相关费用在会计处理方面较以前年度有所变化。两端挤压下,造成公司净利率急速下滑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1761101836256082424","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["91272"],"gpt_icon":0},{"id":"2576853538","title":"長春高新(000661.SZ):注射用GenSci139境內生產藥品臨牀試驗獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2576853538","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576853538?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 18:50","pubTimestamp":1760957414,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新(000661.SZ)公告,公司子公司——长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,同意注射用GenSci139单药在晚期实体瘤患者中开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1357178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","91272","BK0057","BK0028","BK0046","000661","BK0075","BK0239"],"gpt_icon":0},{"id":"2576888708","title":"淨利潤暴跌42%、三費高企46%!長春高新赴港上市難掩「內憂外患」","url":"https://stock-news.laohu8.com/highlight/detail?id=2576888708","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576888708?lang=zh_tw&edition=fundamental","pubTime":"2025-10-20 08:25","pubTimestamp":1760919900,"startTime":"0","endTime":"0","summary":" 当“东北药茅”长春高新的港股招股书在香港交易所披露易网站亮相时,市场并未给出期待中的积极反馈。近三十年A股上市历程中积累的光环,正被生长激素红利消退后的阴影逐渐吞噬,赴港上市能否成为破局关键,眼下仍是未知数。 对于长春高新而言,赴港上市或许能缓解短期资金压力,但无法解决核心的业务困境。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-10-20/doc-infunxxn8395562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000661","91272"],"gpt_icon":0},{"id":"2576087581","title":"長春高新(000661.SZ):注射用GenSci143臨牀試驗申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2576087581","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576087581?lang=zh_tw&edition=fundamental","pubTime":"2025-10-17 16:51","pubTimestamp":1760691086,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新(000661.SZ)公告,公司子公司——长春金赛药业有限责任公司(“金赛药业”)收到美国食品药品监督管理局(“FDA”)书面通知,金赛药业注射用GenSci143临床试验申请获得受理,适应症为:晚期实体瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0057","BK0188","BK0046","BK0028","BK0075","BK0239","91272","000661"],"gpt_icon":0},{"id":"2575785893","title":"昔日超級大牛股長春高新,擬赴港上市!","url":"https://stock-news.laohu8.com/highlight/detail?id=2575785893","media":"市场资讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575785893?lang=zh_tw&edition=fundamental","pubTime":"2025-10-15 18:23","pubTimestamp":1760523780,"startTime":"0","endTime":"0","summary":" 昔日超级大牛股,拟赴港上市! 曾经的超级大牛股长春高新,近日向香港联交所递交了境外上市(H股)申请。 自2021年至今,长春高新股价持续下滑,至今跌幅超过70%。 长春高新销售药品的毛利率从2022年的91.6%,持续下滑至2025年上半年的88.6%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-10-15/doc-inftymnk1982277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0057","BK0188","000661","BK0046","BK0028","BK0075","91272","BK0239"],"gpt_icon":0},{"id":"2575294649","title":"九成收入依賴六款產品,集採後業績暴跌,「東北藥茅」長春高新啓動「A+H」計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=2575294649","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575294649?lang=zh_tw&edition=fundamental","pubTime":"2025-10-14 19:13","pubTimestamp":1760440436,"startTime":"0","endTime":"0","summary":"而随着生长激素被纳入集采范围,核心产品价格直线下滑,如今的长春高新业绩近乎腰斩。除了赖以生存的生长激素暴跌外,长春高新的第二增长曲线疫苗业务也遭遇挫折。因此,目前长春高新的资金流动性良好,2025年上半年,公司经营现金流净额为12.21亿元。截至2025年上半年末,长春高新货币资金达43.65亿元,交易性金融资产16.41亿元,两项合计60.06亿元,而短期借款和一年内到期流动负债合计仅4.01亿元。因此,近年来长春高新在研发投入方面十分慷慨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1760439333904059129","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["91272"],"gpt_icon":0},{"id":"2575408565","title":"長春高新(000661.SZ)子公司三價流感病毒裂解疫苗(BK-01佐劑)臨牀試驗申請獲批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2575408565","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575408565?lang=zh_tw&edition=fundamental","pubTime":"2025-10-13 19:11","pubTimestamp":1760353889,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新(000661.SZ)公告,公司子公司百克生物收到国家药品监督管理局对其三价流感病毒裂解疫苗(BK-01佐剂)下发的《药物临床试验批准通知书》,同意开展预防疫苗相关型别流感病毒引起的流行性感冒的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1354406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0130517989.USD","BK0046","BK0188","BK0075","LU0648001328.SGD","BK0057","BK0239","BK0028","BK4585","BK4559","BK4135","LU1571399168.USD","000661","LU0130102774.USD","159646","91272","BK","LU1201861249.SGD","LU0477156953.USD","BK4588","LU0980610538.SGD","LU1699723380.USD"],"gpt_icon":0},{"id":"2574455073","title":"「東北藥茅」長春高新申請赴港上市,業績滑坡、市值縮水超1600億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574455073","media":"《理财周刊》","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574455073?lang=zh_tw&edition=fundamental","pubTime":"2025-10-11 20:38","pubTimestamp":1760186280,"startTime":"0","endTime":"0","summary":"子公司金赛药业作为公司的“现金奶牛”,贡献长春高新近80%的营收,但其2024年收入下降3.73%,净利润下滑40.67%。市场竞争方面,长春高新面临前所未有的压力。长春高新解释称,这是由于“金赛药业新BU管理架构的调整及相关下一级子公司的设立”导致的。长春高新在财报中披露了体重控制品牌赛必健,包括胃内占容食品、运动营养食品等产品。在此背景下,长春高新赴港上市的战略意义不言而喻。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-10-11/doc-inftprki4820866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","BK0028","BK0075","BK0188","000661","BK0239","91272","BK0057"],"gpt_icon":0},{"id":"2573946610","title":"長春高新押注脱敏市場求解背後:集採壓價與競爭加劇成掣肘","url":"https://stock-news.laohu8.com/highlight/detail?id=2573946610","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573946610?lang=zh_tw&edition=fundamental","pubTime":"2025-10-08 16:06","pubTimestamp":1759910760,"startTime":"0","endTime":"0","summary":" 有着“东北药茅”之称的长春高新,今年上半年延续去年业绩营利双降的业绩颓势。 证券之星注意到,金赛药业依靠生长激素产品,曾年销售额一度超百亿元。但随着竞争加剧、集采压价,金赛药业业绩已难增长。 切入脱敏治疗赛道,可以视为长春高新谋变的之举。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-10-08/doc-inftepri0325843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0075","BK0057","BK0239","BK0028","BK0046","91272","BK0188","000661"],"gpt_icon":0},{"id":"2571694643","title":"天壇生物高管辭職,長春高新擬赴港上市,恆瑞醫藥1類新藥獲批臨牀,羅欣藥業擬定增募資8.42億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2571694643","media":"谈医说药","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571694643?lang=zh_tw&edition=fundamental","pubTime":"2025-09-29 23:48","pubTimestamp":1759160919,"startTime":"0","endTime":"0","summary":"博瑞医药:公司获美国FDA批准开展BGM1812注射液用于超重或肥胖治疗的I期临床。公司于2024年5月13日获得申报受理通知书,并于近日获得国家药监局批准。截至公告日,公司就该药品累计研发投入为843.59万元人民币。该药品为治疗晚期恶性实体肿瘤的基因治疗药物,目前全球共有5个溶瘤病毒药物获得审批上市,国内市场约7个药物处于I/II期临床试验阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930011418a6a6ba5a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250930011418a6a6ba5a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201885.HKD","01276","LU2543165471.USD","LU1023057109.AUD","BK1191","LU0359201612.USD","LU0359202008.SGD","91272","08058"],"gpt_icon":0},{"id":"2571002758","title":"長春高新(000661.SZ)子公司替勃龍片在境內獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2571002758","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571002758?lang=zh_tw&edition=fundamental","pubTime":"2025-09-29 16:20","pubTimestamp":1759134039,"startTime":"0","endTime":"0","summary":"智通财经APP讯,长春高新 发布公告,近日,公司子公司长春金赛药业有限责任公司收到国家药品监督管理局核准签发的《药品注册证书》,其申报的替勃龙片已在境内获批上市。替勃龙片是金赛药业研发的一种组织选择性雌性激素活性调节剂,属于化学药品4类口服片剂,用于治疗妇女自然绝经和手术绝经所引起的低雌激素症状。金赛药业研发的替勃龙片是针对当前未满足的市场和临床需求研发的一款仿制药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350569.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0075","BK0046","91272","BK0188","BK0239","BK0028","000661","BK0057"],"gpt_icon":0},{"id":"2571801518","title":"新股消息 | 長春高新衝刺港交所,連續8年躋身「中國醫藥工業百強企業排行榜」","url":"https://stock-news.laohu8.com/highlight/detail?id=2571801518","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571801518?lang=zh_tw&edition=fundamental","pubTime":"2025-09-29 14:43","pubTimestamp":1759128215,"startTime":"0","endTime":"0","summary":"长春高新已经在深交所上市。招股书显示,长春高新是中国领先的创新驱动型医药集团,业务覆盖治疗性生物制剂、化学药品、疫苗及中成药,涵盖中国所有主要药物注册类型。2024年,长春高新的制药产品销售收入达到人民币127亿元,连续四年实现人民币100亿元以上规模。自2017年起,长春高新连续8年跻身“中国医药工业百强企业榜单”。长春高新亦积极扩大已获批产品的适应症覆盖范围,以针对更广泛的患者人群。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350516.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","600056","BK0239","BK0185","91272","BK0250","BK0046","BK0175","BK0010","BK0082","000661","BK0028","BK0075","BK0057"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":21,"code":"91000000","status":"200"}]}}